Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KGX101 Monotherapy and Combination With Envafolimab in Advanced Solid Tumors
NCT06074497Phase 1Active, not recruiting
- Sponsor
- KangaBio
- Start
- Dec 2023
- Primary completion
- May 2026
- Modality
- Cytokines & Interferons, Prodrugs/Conditional Activator Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of KGX101 in solid tumor (7 arms), sponsored by KangaBio. Primary endpoints: Treatment-Emergent Adverse Events, Dose Limiting Toxicities at 4 weeks and 2 more. Started Dec 2023; status: active, not recruiting.
02
Drugs
KGX101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06074497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06074497.